Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study
- PMID: 20833867
- PMCID: PMC2992194
- DOI: 10.2337/dc10-0842
Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study
Abstract
Objective: Previous observational studies have found an increased risk of acute pancreatitis among type 2 diabetic patients. However, limited information is available on this association and specifically on the role of antidiabetic treatment. Our aim, therefore, was to further assess the risk of acute pancreatitis in adult patients with type 2 diabetes.
Research design and methods: We performed a population-based case-control analysis nested in a cohort of 85,525 type 2 diabetic patients and 200,000 diabetes-free individuals from the general population using data from The Health Improvement Network database. Subjects were followed up to ascertain incident cases of acute pancreatitis.
Results: We identified 419 cases of acute pancreatitis, 243 in the general population and 176 in the diabetes cohort. Incidence rates were 30.1 and 54.0 per 100,000 person-years in the general population and the diabetes cohort, respectively. In the cohort analysis, the adjusted incidence rate ratio of acute pancreatitis in diabetic patients versus that in the general population was 1.77 (95% CI 1.46-2.15). The magnitude of this association decreased with adjustment for multiple factors in the nested case-control analysis (adjusted odds ratio 1.37 [95% CI 0.99-1.89]). Furthermore, we found that the risk of acute pancreatitis was decreased among insulin-treated diabetic patients (0.35 [0.20-0.61]).
Conclusions: Type 2 diabetes may be associated with a slight increase in the risk of acute pancreatitis. We also found that insulin use in type 2 diabetes might decrease this risk. Further research is warranted to confirm these associations.
Figures
Similar articles
-
Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.Lancet Diabetes Endocrinol. 2014 Feb;2(2):111-5. doi: 10.1016/S2213-8587(13)70147-5. Epub 2013 Nov 12. Lancet Diabetes Endocrinol. 2014. PMID: 24622714
-
Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan.Am J Gastroenterol. 2011 Sep;106(9):1697-704. doi: 10.1038/ajg.2011.155. Epub 2011 May 17. Am J Gastroenterol. 2011. PMID: 21577242
-
Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.Diabetes Obes Metab. 2014 Sep;16(9):801-11. doi: 10.1111/dom.12282. Epub 2014 Mar 19. Diabetes Obes Metab. 2014. PMID: 24612200
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
[Diabetes and cancer risk: oncologic considerations].Orv Hetil. 2011 Jul 17;152(29):1144-55. doi: 10.1556/OH.2011.29158. Orv Hetil. 2011. PMID: 21712179 Review. Hungarian.
Cited by
-
Glucagon-like peptide-1 receptor agonists in neoplastic diseases.Front Endocrinol (Lausanne). 2024 Sep 20;15:1465881. doi: 10.3389/fendo.2024.1465881. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39371922 Free PMC article. Review.
-
Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database.Front Pharmacol. 2024 May 27;15:1364110. doi: 10.3389/fphar.2024.1364110. eCollection 2024. Front Pharmacol. 2024. PMID: 38860168 Free PMC article.
-
Relationship of circulating levels of long-chain fatty acids to persistent organ failure in acute pancreatitis.Am J Physiol Gastrointest Liver Physiol. 2023 Sep 1;325(3):G279-G285. doi: 10.1152/ajpgi.00074.2023. Epub 2023 Jul 18. Am J Physiol Gastrointest Liver Physiol. 2023. PMID: 37461868 Free PMC article.
-
Causal associations between modifiable risk factors and pancreatitis: A comprehensive Mendelian randomization study.Front Immunol. 2023 Mar 14;14:1091780. doi: 10.3389/fimmu.2023.1091780. eCollection 2023. Front Immunol. 2023. PMID: 36999014 Free PMC article.
-
Hypertriglyceridaemia-Induced Acute Pancreatitis: A Different Disease Phenotype.Diagnostics (Basel). 2022 Mar 31;12(4):868. doi: 10.3390/diagnostics12040868. Diagnostics (Basel). 2022. PMID: 35453916 Free PMC article.
References
-
- Spanier BW, Dijkgraaf MG, Bruno MJ: Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol 2008;22:45–63 - PubMed
-
- Yadav D, Lowenfels AB: Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas 2006;33:323–330 - PubMed
-
- Blomgren KB, Sundström A, Steineck G, Wiholm BE: Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 2002;25:298–302 - PubMed
-
- Eland IA, Sundström A, Velo GP, Andersen M, Sturkenboom MC, Langman MJ, Stricker BH, Wiholm B: EDIP Study Group of the European Pharmacovigilance Research Group Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP). Scand J Gastroenterol 2006;41:1484–1490 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
